Obatala Sciences develops patented and patent-pending human-derived hydrogels, adult human stem cells from a diverse biobank, media for cell growth and differentiation, and tissue chip kits (including fat-on-chip and pancreas-on-a-chip under development) for research and drug discovery. The company’s products are sold to pharmaceutical companies, government labs, and academic researchers to provide more predictive, human-based data across diverse populations. Obatala positions its solutions as a response to limitations of 2D cell culture and animal-derived data, aiming to reduce failure rates and time to market for therapeutics. The company was founded in 2017 and is based in New Orleans. Its stated near-term plans include commercialization of pipeline products, building out a lab at The Beach at UNO research park, obtaining ISO certifications, and expanding North American and international distribution. Management also plans to deepen sales, marketing, and customer support teams to support a growing global customer base.

Total raised

$3M

Funding rounds

1

Latest round

Series A

Latest activity

Oct 2022